The increase in expression of activating FcγRs in the membrane is of importance, since patients with active CLL have a dominance of FcγRIIb signaling, which can lead to decreased antibody-mediated activity (5, 69, 70). The gene discussed is FCGR2B; the disease is B-cell chronic lymphocytic leukemia.